Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation
- PMID: 15042010
- DOI: 10.1016/j.ajog.2003.09.037
Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation
Abstract
Objective: Our purpose was to compare the effectiveness, women's views of the termination procedure, and success of umbilical cord culture for vaginal and oral misoprostol versus intra-amniotic prostaglandin PGF(2alpha) for second-trimester pregnancy termination (STPT).
Study design: We randomized 217 women, 15 to 24 weeks' gestation, into 3 groups. Oral (OM) and vaginal (VM) misoprostol groups received 400 microg of misoprostol every 4 hours for 24 hours. The intra-amniotic PGF(2alpha) (IAPG) group received 40 mg of PGF(2alpha) followed by oxytocin infusion. Women completed self-administered questionnaires 3 weeks after the termination procedure. Umbilical cord samples were collected at delivery for karyotype analysis. The primary outcome was the time from start of the procedure to placental delivery. Secondary outcomes were maternal complications, women's acceptance of the termination procedure, and success rates of umbilical cord culture.
Results: The time was longer for the OM group (30.5+/-14.4 hours) compared with the VM group (18.3+/-8.2 hours) and the IAPG group (21.1+/-10.2 hours), P<.001 for both comparisons. Women in the VM group reported being more willing to repeat the termination method in the future and reported fewer side effects than those in the other groups, P<.001. Failure rates for umbilical cord cultures were 9.6%, 17.0%, and 45.6% for the VM, OM, and IAPG groups, respectively.
Conclusion: Oral misoprostol is less effective than intra-amniotic PGF(2alpha) or vaginal misoprostol for STPT. Women report vaginal misoprostol more acceptable than other methods. Umbilical cord culture failure rate is highest in the IAPG group.
Similar articles
-
Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second-trimester labor induction.Obstet Gynecol. 2004 Jul;104(1):138-45. doi: 10.1097/01.AOG.0000128947.31887.94. Obstet Gynecol. 2004. PMID: 15229013 Clinical Trial.
-
A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2alpha analogue for second-trimester induction termination in Uzbekistan.Contraception. 2007 Dec;76(6):461-6. doi: 10.1016/j.contraception.2007.08.004. Epub 2007 Nov 9. Contraception. 2007. PMID: 18061705 Clinical Trial.
-
[Oxytocin and misoprostol administered intravaginally for termination of pregnancy at 13 to 29 weeks of amenorrhea. A prospective randomized trial].J Gynecol Obstet Biol Reprod (Paris). 2001 Sep;30(5):439-43. J Gynecol Obstet Biol Reprod (Paris). 2001. PMID: 11598557 Clinical Trial. French.
-
Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure.Clin Dysmorphol. 1999 Jan;8(1):53-8. Clin Dysmorphol. 1999. PMID: 10327252 Review.
-
Prostaglandins: overview in obstetrics and gynecology.J Reprod Med. 1974 May;12(5):211-4. J Reprod Med. 1974. PMID: 4599109 Review.
Cited by
-
Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death.Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD004901. doi: 10.1002/14651858.CD004901.pub2. Cochrane Database Syst Rev. 2010. PMID: 20393941 Free PMC article.
-
Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis.Contracept X. 2020 Aug 20;2:100037. doi: 10.1016/j.conx.2020.100037. eCollection 2020. Contracept X. 2020. PMID: 32954250 Free PMC article. Review.
-
Influence of Mifepristone in Induction Time for Terminations in the Second and Third Trimester.Geburtshilfe Frauenheilkd. 2014 Apr;74(4):350-354. doi: 10.1055/s-0033-1360361. Epub 2014 Mar 28. Geburtshilfe Frauenheilkd. 2014. PMID: 25076791 Free PMC article.
-
Medical methods for mid-trimester termination of pregnancy.Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD005216. doi: 10.1002/14651858.CD005216.pub2. Cochrane Database Syst Rev. 2011. PMID: 21249669 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical